Abeona Therapeutics Inc. — 2018 Form 10-K
Reporting period: Fiscal year ended December 31, 2018. This is an annual filing; quarterly data include the three months ended December 31, 2018 (Q4). Abeona is a clinical-stage biopharmaceutical company developing cell and gene therapies for rare genetic diseases. Its lead programs are EB-101 for RDEB and ABO-102 and ABO-101 for Sanfilippo syndrome types A and B.
Financial performance and liquidity
| Metric | 2018 | 2017 |
|---|---|---|
| Total revenue | $3.0 million | $0.84 million |
| Research and development | $38.7 million | $17.0 million |
| General and administrative | $20.1 million | $10.9 million |
| Operating loss | $58.2 million | $27.8 million |
| Net loss | $56.7 million | $27.3 million |
| Basic and diluted loss per share | $1.19 | $0.66 |
| Cash, cash equivalents and short-term investments at year-end | $85.0 million | $138.8 million |
| Working capital at year-end | $68.5 million | $135.0 million |
- 2018 revenue included $2.8 million of Sanfilippo foundation revenue and $0.2 million of MuGard royalties; no license revenue was recognized under the new accounting standard. Revenue remains minimal relative to development costs.
- Cash used in operating activities was $39.1 million; capital expenditures were $9.2 million. Cash and cash equivalents alone were $18.8 million, with $66.2 million in short-term investments.
- Current assets were $88.9 million and current liabilities $20.4 million. The filing reports no conventional borrowing balance; liabilities include $30 million payable to REGENXBIO, of which $10 million was current and $20 million noncurrent.
- No meaningful operating margin or profitability was reported: the company remains loss-making and reports no material product-sales base.
Q4 2018: Revenue was approximately $482,000 ($369,000 foundation revenue and $113,000 royalties); operating loss was $18.0 million, net loss $17.5 million, and loss per share $0.36.
Material changes and notable items
- Research and development spending rose $21.7 million year over year, principally from increased clinical and development work, staffing, stock-based compensation and consulting. General and administrative expense rose $9.2 million, including higher personnel costs, professional fees and stock compensation.
- Operating cash outflow increased from $22.7 million in 2017 to $39.1 million in 2018. Year-end cash, cash equivalents and short-term investments declined by $53.8 million; the company attributed working-capital reduction principally to operations, facility investment and the REGENXBIO license.
- Adoption of ASC 606 increased opening 2018 stockholders’ equity by $6.275 million and changed revenue timing. The company recognized foundation revenue as related work-plan costs were incurred and recognized legacy license revenue at the point the licenses were granted. Q1 and Q2 2018 quarterly figures were corrected for an ASC 606 transition error, reducing foundation revenue and increasing reported losses in those quarters.
- Abeona entered a REGENXBIO NAV AAV9 license covering MPS IIIA, MPS IIIB, CLN1 and CLN3. It paid $10 million at signing, owed another $10 million by November 2019, and recorded $20 million of guaranteed future annual fees. The agreement also provides for up to $60 million in commercial milestones and low double-digit royalties on net sales.
- The Cleveland manufacturing build-out drove capital spending and increased property and equipment to $9.4 million. The company stated that the facility was not yet commercially validated.
Outlook, management commentary and risks
- Management expected continuing losses and substantial research, clinical and manufacturing spending. It stated that existing resources were expected to support operations for the foreseeable future, while also describing a liquidity program intended to secure funding through at least the end of 2020. That program could include equity financing, out-licensing, expenditure reductions, restructuring or asset sales; additional capital will be required for approval and commercialization.
- Management expected to initiate the EB-101 VITAL Phase III study in mid-2019, planned for 10–15 patients. ABO-102 Phase I/II data showed sustained biomarker and liver-volume reductions, with encouraging neurocognitive signals in younger, higher-functioning patients; no treatment-related serious adverse events had been reported at the time described. ABO-101 remained in early clinical development.
- Key risks include clinical efficacy and safety uncertainty, patient recruitment for rare diseases, regulatory review, gene-therapy manufacturing scale-up and cGMP compliance, dependence on third parties, intellectual-property and licensing exposure, and the need for further financing and potential dilution. Coverage, reimbursement and eventual market acceptance are uncertain.
- Contingencies included shareholder derivative litigation concerning director compensation, with a proposed settlement involving governance reforms and attorneys’ fees of up to $240,000 subject to court approval. A separate arbitration dispute concerned a claimed obligation to provide EBRP 350,000 unrestricted shares; the company stated it intended to defend the claim. The filing does not provide a clear estimate of potential exposure for the arbitration.
- The company reported effective disclosure controls and internal control over financial reporting; the auditor gave unqualified opinions on the financial statements and internal controls.
Important facts for investors to verify
- Whether cash runway and the stated funding plan remain adequate against operating burn, contractual commitments and trial expansion needs.
- Clinical progress, enrollment and safety for EB-101, ABO-102 and ABO-101, including whether planned trial timelines and endpoints are achieved.
- Manufacturing readiness, cGMP validation, product supply and the risks of having no backup EB-101 manufacturer.
- The full timing and conditions of REGENXBIO fees, royalties and milestones, and the outcome and financial impact of the EBRP arbitration and shareholder litigation.
- How revenue comparisons are affected by ASC 606 adoption and the disclosed Q1/Q2 2018 corrections.